ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021

Conference call and webcast on Wednesday, May 5, 2021 at 8:30am EST/ 2:30pm CET

  • TRYbeCA-1, Phase 3 clinical trial in 2nd line pancreatic cancer, fully enrolled, and on track for final results in Q4 2021
  • Pre-BLA meeting with FDA requested to discuss the potential submission of a Biologics License Application (BLA) for eryaspase in hypersensitive ALL in the second half of this year
  • First dose cohort in Phase 1 Investigator Sponsored Trial (IST) in 1st line pancreatic cancer completed with no dose limiting toxicity; encouraging signs of clinical activity observed
  • Cash and cash equivalents of €37.4 million ($43.9 million) at the end of March 2021
  • Successful registered direct round of $ 30 million with specialized healthcare investors in April 2021
  • Cash horizon extended to mid 2022, beyond anticipated key catalysts
Menu